Key result
The proportion of atrial fibrillation patients receiving a DOAC steadily increased from 3.9% among oral anticoagulant users in Q3 2011 to 67.6% in Q2 2015 (P<.001).
Cohort (n=2,261)
No
Absolute Event Rate: 67.6% vs 3.9%
p-value: p=<.001
Following their introduction, DOACs rapidly became the most commonly prescribed antithrombotic for atrial fibrillation, though they were preferentially initiated in younger, lower-risk patients compared to warfarin.
No takes yet. Share an insight, caveat, or question.
Marked rise in DOAC prescribing for AF supports adoption trends; leaves open selection factors and outcome impact in real-world cohorts.
Alamneh et al. (2017) conducted a cohort in Atrial fibrillation (n=2,261). Direct oral anticoagulants (DOACs) vs. Warfarin and antiplatelet agents was evaluated on Proportion of patients receiving a DOAC among oral anticoagulant users (p=<.001). The proportion of atrial fibrillation patients receiving a DOAC steadily increased from 3.9% among oral anticoagulant users in Q3 2011 to 67.6% in Q2 2015 (P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: